ICI represents a revolutionary breakthrough in cancer therapy, wherein the PD-1/PD-L1 axis plays a direct role in cancer immune modulation and is considered among the most pertinent immune checkpoint inhibitors [8]. The gene discussed is PDCD1; the disease is cancer.